RE:RE:RE:RE:RE:TH2101In the new corporate presentation, there is a line about combo therapies with immunotherapy drugs, But it talks about using both drugs in combination, not linking a monoclonal antibody to TH19P01. It reads as follow:
Explore rational combinations of SORT1+ TechnologyTM with other treatments, especially immunotherapies Wino115 wrote: Absolutely, and I think in this case 1+1=5. The POC would get the interest of other producers with newer toxins or immunotherapy drugs that want a vastly superior delivery mechanism for their drug in advanced cases with high Sortilin. If there is some additional benefits to interacting with Sortilin as THYX says with VM and mestaticism, then even better.
Trodelvy targets TROP1 or 2. I like the fact they are moving beyond the old line toxins and looking at some newer ones. SN38 is a fairly new discovery. I bet we hear about an immunotherapy drug and a TKI in 2022.
jfm1330 wrote: I forgot this was the cytotoxic agent in the Immunomedic ADC, even though I saw it was very potent. Now, as the codename suggests, they have this molecule since January of this year, so they likely already have some animal data with it. Now, if Thera can come with a clear proof of concept with TH1902, the then they come out with spectacular animal data with with TH2101. 1+1=2. It would really strongly push forward the idea that they have a platform able to generate multiple PDCs aiming at an extraordinary target which is sortilin. Some PDCs that will likely be better than TH1902, also, down the road, PDCs that could be used in combo therapies. That's why the proof of concept is so important.
Wino115 wrote: This would also really help but parameters around the program and and u Delhi get possible valuation metric. Certainly narrows that unknown future value that we and the market don't quite have a handle on now. Putting that comp up there makes it really easy for analysts to justify rather large values.
Wino115 wrote:
This is strategically very ballsy! I haven't been able to read the new deck, but this is potentially huge. The reason? That cytotoxic is what is on the ADC Immunomedics created that was bought by Gilead for $21bil. And we know its name -Trodelvy. This would be the Trodelvy killer!
So the industry and FDA gushed over the Trodelvy science for mTNBC and it was approved after a brief P3 reading backed up the P2 data. But the toxin escapes and ends up in the digestive tract causing bad nausea and diarrhea. I believe the FDA sent back some of their early science trials because of that. So if this concentrates the drug in the tumor better with less effllux and better safety, it will crush Trodelvy. Absolutely kill it on day 1. Gilead needs $5bil+ annual revenue to justify their $21bil price tag. No way if this works.
This would prove up the entire platform for THTX and get AApproval for each program. So what do you pay for a platform that works on way more than one cancer type and with many CYTO toxins? Far more than $21bil in my book and I hope the BOD knows that!
jfm1330 wrote: On new information in the updated corporate presentation is the identity of a new PDC made out of TH19P01. It was given the codename TH2101, which likely mean it was the first research molecule made by Thera in 2021, jusy my guess. That being said, they also revealed with is the cytotoxic drud that is attached to TH19P01, and it is a molecule called SN38, which is the active metabolite of a drug called Irinotecan. This is a topoisomerase I inhibitor and it is 1000 times more active than irinotecan.
https://en.wikipedia.org/wiki/SN-38